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Background
Angiogenesis is a physiological process of generation of new blood vessels required 
for normal body functioning, such as wound healing, endometrial growth during the 
menstrual cycle, tissue grafting, inflammation, and hypoxia. However, clinically and 
pathologically it has been demonstrated as a basic prerequisite for sustainable growth, 
proliferation and metastatic spread of solid tumours [1]. Cascade of events activated 
by several pro-angiogenic factors produced by hypoxic tumour cells happens during 
tumour angiogenesis including dissolution of vascular basal membrane, increased vascu-
lar permeability and degradation of extracellular matrix (ECM) resulting in endothelial 
Abstract 
Background: Angiogenesis, a process of generation of new blood vessels from the 
pre-existing vasculature, has been demonstrated to be a basic prerequisite for sustain-
able growth and proliferation of tumour. Anti-angiogenic treatments show normaliza-
tion of tumour vasculature and microenvironment at least transiently in both preclini-
cal and clinical settings.
Methods: In this study, we proposed a multi-scale mathematical model to simulate 
the dynamic changes of tumour microvasculature and microenvironment in response 
to anti-angiogenic drug endostatin (ES). We incorporated tumour growth, angio-
genesis and vessel remodelling at tissue level, by coupling tumour cell phenotypes 
and endothelial cell behaviour in response to local chemical and haemodynamical 
microenvironment.
Results: Computational simulation results showed the tumour morphology and 
growth curves in general tumour progression and following different anti-angiogenic 
drug strategies. Furthermore, different anti-angiogenic drug strategies were designed 
to test the influence of ES on tumour growth and morphology. The largest reduction of 
tumour size was found when ES is injected at simulation time 100, which was concom-
itant with the emergence of angiogenesis phase.
Conclusion: The proposed model not only can predict detailed information of chemi-
cals distribution and vessel remodelling, but also has the potential to specific anti-
angiogenic drugs by modifying certain functional modules.
Keywords: Multi-scale mathematical model, Numerical simulation, Solid tumour 
growth and angiogenesis, Tumour microenvironment, Anti-angiogenic therapy
Open Access
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and 
indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdo-
main/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
RESEARCH
Cai et al. BioMed Eng OnLine 2016, 15(Suppl 2):155
DOI 10.1186/s12938‑016‑0275‑x BioMedical Engineering
OnLine
*Correspondence:   
yancai@seu.edu.cn 
2 School of Biological 
Sciences and Medical 
Engineering, Southeast 
University, 2 Sipailou, 
Nanjing 200018, China
Full list of author information 
is available at the end of the 
article
Page 686 of 700Cai et al. BioMed Eng OnLine 2016, 15(Suppl 2):155
cell (EC) migration, invasion, proliferation and tube formation [2]. The growth of new 
blood vessels requires the concerted action of activators and inhibitors of angiogene-
sis. Chemicals that can activate angiogenesis include vascular endothelial growth factor 
(VEGF), matrix metalloproteinases (MMPs), placenta growth factor (PlGF), fibroblast 
growth factor (FGF) and hepatocyte growth factor (HGF) [3]. Endogenous inhibitors of 
angiogenesis include angiostatin (AS) and endostatin (ES) [4]. The imbalance between 
angiogenic growth factors and inhibitors is believed to be significantly important in the 
development of the tumour vasculature [5].
Given the prominent role of angiogenesis in cancer, many cancer therapies aim to 
block angiogenesis and thereby inhibit tumour growth. These approaches undertaken 
towards that goal include inhibition of growth factors required for ECs proliferation and 
survival, such as VEGF [6]; inhibition of MMPs [7]; or direct inhibition of EC migration 
[8]. In addition, vascular disrupting agents (VDA) have been shown to inhibit tumour 
growth through induction of vascular collapse [9]. This research was transformed into 
therapeutic modality which led to the development of bevacizumab (Avastin), the first 
VEGF targeted anti-angiogenesis cancer therapy, and approved by the FDA in 2004 [10].
While the anti-angiogenic therapy have been approved for cancer treatment, it appears 
that the clinical application of anti-angiogenic therapy is more complex than originally 
thought. Since the anti-angiogenic drugs target tumour vasculatures without tumour 
cells, resistance to anti-angiogenic therapy caused by the pathological microenviron-
ment in tumour is a prominent issue which may explains the variable results observed 
in the experiment and clinic using this approach [11]. Unlike normal blood vessels, 
tumour vasculature has abnormal structure and function [12]. The microvessels inside 
the tumour are leaky, which causes the high interstitial fluid pressure (IFP) in tumours. 
The blood perfusion in the abnormal microvasculature is heterogeneous and often com-
promised [13]. In addition, host-tumour interactions regulate the dynamic balance of 
angiogenic growth factors and inhibitors and result in the pathophysiological charac-
teristics of the tumour [14]. Therefore, it is important to understand the mechanisms of 
interactions between tumour cells and microenvironment in response to anti-angiogenic 
therapy.
Mathematical modelling and numerical simulation offer powerful tools with which to 
study complex biological processes, such as tumour growth and angiogenesis. Billy et al. 
[15] developed a model of tumour growth that includes inhibitors (ES and Ang2) and 
promoters (VEGF and Ang1) of angiogenesis. Sleeman and coworkers’ [16] recent study 
proposed a model that combined angiogenesis and haemodynamic simulations in meta-
static tumours. Their model predicted that treatment with angiostatin affected tumour 
vessels through the process called ‘vessel normalization’. Jain and coworkers developed a 
model to predict changes in tumour microenvironment including interstitial fluid pres-
sure after vessel normalization treatment [17, 18]. Alarcon et al. [19] proposed a model 
of VEGFR association with VEGF and internalization to investigate how these processes 
influence the response to anti-angiogenic therapy. Using numerical algorithms, such as 
partial differential equations, agent-based modelling, and continuous–discrete hybrid 
modelling, computational modelling and numerical simulation provide platforms to 
study the complexity of tumour growth and angiogenesis process and the therapeutic 
strategies of anti-angiogenesis in cancer.
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Based on the continuous–discrete hybrid model proposed by Chaplain’s group for 
modelling angiogenesis [20], we started our work by investigating the dynamic inter-
actions between local haemodynamics and angiogenesis in a 2D model [21] and then 
developed it to a 3D model [22]. The inclusion of different tumour cell phenotypes into 
the angiogenesis simulation forms our second generation of model in which the tumour 
growth, vessel remodelling and blood perfusion were incorporated [23]. The present 
study is a further development in which a multi-scale 3D model was established aiming 
to simulate the dynamic changes of tumour microvasculature and microenvironment 
in response to anti-angiogenic therapy. The model focused on the anti-angiogenic drug 
endostatin (ES), which can inhibit endothelial cell (EC) proliferation, migration, inva-
sion and tube formation. We envision that the proposed model will serve as a simulation 
framework for studying tumour growth and the changes of tumour microenvironment 
in response to anti-angiogenic therapy.
Mathematical model and methods
Multi-scale 3D tumour modelling is utilized to detail the mechanisms of tumour growth 
and angiogenesis. We have organized our model into three levels: tissue, intratumoral 
and cellular layers. The overall structure of this model is summarized in Fig. 1. In the 
tissue layer, we deal with the morphology of solid tumour and the structural proper-
ties of the vascular network. Four different phenotypes of tumour cells with correspond-
ing metabolic characteristics are introduced in “Tumour growth” section. Modelling of 
tumour angiogenesis due to endothelial cell proliferation and migration is presented 
in “Angiogenesis and vessel remodelling” section. In addition, vessel remodelling in 
response to varied microenvironment is also considered in “Angiogenesis and vessel 
remodelling” section. The tissue level and the cellular level are coupled by the changes 
of microenvironment in the intratumoral level, including chemicals concentration flied 
(“Chemical microenvironment” section) and haemodynamic information (“Haemo-
dynamical microenvironment” section). In “Anti-angiogenic therapy” section, we will 
develop the multi-scale model with anti-angiogenic drug delivery to investigate the 
influence of anti-angiogenic therapy on the tumour growth. Initial conditions and simu-
lation algorithm are given in “Simulation setup” section.
Fig. 1 Structure of multi-scale modelling system
Page 688 of 700Cai et al. BioMed Eng OnLine 2016, 15(Suppl 2):155
Tumour growth
The probabilistic hybrid model for tumour cell growth is based on the previous work 
[23]. We assumed four different phenotypes of tumour cells: the proliferative cells (PC), 
the quiescent cells (QC), the necrotic cells (NC) and the migrating cells (MC). Two 
thresholds of oxygen concentration for cell proliferation (θprol) and cell survival (θsurv) 
are introduced to describe the effects of oxygen field on the tumour cell actions. Each 
phenotype of tumour cell has a different coefficient of oxygen consumption rate and the 
production rate of VEGF and MDEs (Table 1) [24].
Proliferative cells (PC)
If there is enough oxygen (Cexo ≥ θprol) and space is available, a tumour cell will prolifer-
ate into two daughter cells with a probability, defined as Tage/TTC. Tage is the tumour cell 
age, ranging from 1 to TTC and with an incremental 1 in each simulation time step. TTC 
is the tumour cell proliferation time (set to be 9 h, equal to six time steps). One of the 
two daughter cells will replace the parent cell and the other cell will move to a neigh-
bouring element.
Quiescent cells (QC)
When a tumour cell satisfies the survival condition but there is no neighbouring space 
for it to proliferate, it will go quiescent. When the neighbouring space of one quiescent 
cell has been released, the quiescent cell will turn back into a proliferating cell if the local 
oxygen supply is sufficient.
Necrotic cells (NC)
When the local oxygen concentration at a tumour site is less than the cell survival 
threshold θsurv, the tumour cell is marked as a necrotic cell and will not be revisited at 
the next time step. A necrotic cell has a probability of 20% to disappear and release the 
space for a tumour cell or an endothelial cell if it stays necrotic for more than 45 h (30 
time steps).
Migrating cells (MC)
When local oxygen level is higher than θsurv but lower than θprol and a space is avail-
able, a proliferating cell has a probability (50%) to become a migrating cell (MC), and 
will migrate to a neighbouring space which has the highest oxygen concentration in the 
neighbouring elements. It was also assumed that the migrating cells adjacent to the pre-
existing vessel wall have higher probability of moving in the longitudinal direction (ves-
sel axial direction) than the radial direction. The migration speeds of the two directions 
Table 1 Parameters of different phenotypes of tumour cells
Phenotypes MDE production VEGF production Oxygen consumption
Migrating cells (M) 2μT χ × 4 2γ
Proliferating cells (P) μT χ γ
Quiescent cells (Q) μT/5 χ × 2 γ/2
Necrotic cells (N) μT/10 χ × 4 γ/4
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are the same. After a migrating cell completes its movement, the space it originally occu-
pied will be released for other cells.
Angiogenesis and vessel remodelling
A 3D hybrid discrete–continuum angiogenesis model was adopted to investigate the EC 
migration and proliferation through random motility, chemotaxis in response to VEGF 
distributions and haptotaxis in response to the local ECM density [20]. Endothelial 
sprouting is only allowed in immature vessels, and the endothelial cell distribution was 
updated based on the equation
where e is the EC density. De, φc, φh are EC diffusion, chemotaxis and haptotaxis coeffi-
cients, respectively. ECs are allowed to move along the six directions in a 3D space.
In our model, we consider vessel dilation as the first sign of a pre-existing vessel 
becoming an immature vessel. A vessel segment inside the tumour has a VEGF concen-
tration larger than a threshold θVEGF will increase its radius R with the rate of 0.4 µm h−1 
which will stop when the vessel radius reaches the maximum value of Rmax = 10 µm [25]. 
At the same time, the permeability of the vessel wall Lp is increasing in a dilation vessel, 
and satisfies
where LNp  is the initial value of Lp referred to the vessel permeability value in the normal 
tissue; LTp  is the maximum value of Lp according to the experiments of vessel permeabil-
ity value in a tumour microvessel.
For a pre-existing vessel, once vessel dilation occurs, the vessel segment is treated as an 
immature vessel with increased Lp. In the simulation, vessel wall compliance is defined 
by the radius changing under the influence of intravascular and interstitial pressures and 
collapse pressure based on the empirical equation of Netti et al. [26].
where R0 is the origin radius of the capillary; Pc is the collapse pressure; b is the compli-
ance exponent; E is the compliance coefficient. The intravascular and interstitial pres-
sures are calculated by fully coupled haemodynamic simulation, which will be detailed in 
“Haemodynamical microenvironment” section.
Based on the above equations, when the vessel segment becomes immature, Lp will 
increase which causes higher Pi, and consequently vessel will be compressed. A com-
pressed vessel, on the other hand will induce a higher flow resistance, lower flow which 
will then decrease the wall shear stress (WSS) level for the vessel. Vessel collapse will 
occur by either a significant reduced R or WSS criteria [24].
(1)
∂e
∂t
= De∇
2e−∇ ·
(
φc
1+ σCv
e∇Cv + φhe∇Cf
)
(2)Lp =
{
LTP
(
1−
Rmax−R
Rmax
)
, immature vessel
LNP , mature vessel
(3)R =
{
R0
(
Pv−Pi+Pc
E
)b
, immature vessel
R0, mature vessel
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Chemical microenvironment
The tumour cell and endothelial cell behaviours are coupled by the changes of the chem-
icals in the extra-cellular matrix (ECM), such as oxygen, VEGF and matrix degradation 
enzymes (MDEs) [24]. The transport of these chemicals (oxygen, VEGF and MDEs) are 
modelled by quasi-steady reaction–diffusion equations. The ECM is treated as a con-
tinuous substance and can be degraded by MDEs, while the MDEs are governed by dif-
fusion, produced by TCs and ECs, and the decay of itself. The equations describing the 
interactions of TCs and ECs with ECM, MDE and VEGF are
where Cf, Cm, Cv are the ECM, MDE and VEGF concentration, separately. The TCi,j and 
ECi,j terms represent a tumour cell and an endothelial cell located at a node position (i, j). 
Their values are either 1 if a cell is present or 0 if it is not. Dm is the MDE diffusion coef-
ficient. Dv is VEGF diffusion coefficient. δ, μT, μE, λm, χ, ξ, ɛ, λv are positive constants.
To obtain a more realistic oxygen concentration field, the advection and diffusion of 
oxygen in the vessel network are introduced [27]. The computational space is separated 
into three domains to characterize three distinct physiological processes, which are (a) 
the oxygen advection equation inside the vessel, (b) the oxygen flux across the vessel wall 
and (c) the free oxygen diffusion in the tissue. The detailed equations and methodology 
of oxygen delivery can be found in Cai et al. [28].
Haemodynamical microenvironment
The haemodynamic model in this study is based on our previous work on the coupled 
modelling of intravascular blood flow with interstitial fluid flow [21, 22]. Briefly, the 
basic equation for the intravascular blood flow is the flux concentration and incompress-
ible flow at each node. Flow resistance is assumed to follow Poiseuille’s law in each vessel 
segment. The interstitial fluid flow is controlled by Darcy’s law. The intravascular and 
interstitial flow is coupled by the transvascular flow, which is described by Starling’s law. 
Blood viscosity is a function of vessel diameter, local haematocrit, and plasma viscosity 
[29]. In addition, vessel compliance and wall shear stress are correlated to vessel remod-
elling and vessel collapse (see “Angiogenesis and vessel remodelling” section).
The main equations for blood flow calculation are as follows:
(4)
∂Cf
∂t
= −δCmCf
(5)
∂Cm
∂t
= Dm∇
2Cm + µTTCi,j + µEECi,j − mCm
(6)
∂Cv
∂t
= Dv∇
2Cv + χTCi,j + ξCf − ǫECi,j − vCv
(7)Qv =
πR4Pv
8µl
(8)Qt = 2πR ·�l · Lp(Pv − Pi − σT(πv − πi))
(9)Q = Qv −Qt
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where Q is the flow rate of each vessel segment, which has a value zero at each node of 
the vessel network due to the assumption of flux conservation and incompressible flow. 
Qv is the vascular flow rate without fluid leakage; Qt is the transvascular flow rate. l and 
R are the mean length and radius of the vessel segment. Pv and Pi are the intravascular 
pressure and the interstitial pressure, respectively. Lp is the hydraulic permeability of the 
vessel wall. σT is the average osmotic reflection coefficient for plasma proteins; πv and πi 
are the colloid osmotic pressure of plasma and interstitial fluid, respectively.
The velocity of intravascular Uv and interstitial flow Ui satisfies
where K is the hydraulic conductivity coefficient of the interstitium; S/V is the surface 
area per unit volume for transport in the interstitium.
Anti‑angiogenic therapy
Endostatin (ES), identified in mice by O’Reilly et al. [30] in 1997, has been considered 
as one of the most potential anti-angiogenic drugs. It can inhibit endothelial cell prolif-
eration, migration, invasion and tube formation. In the present model, EC apoptosis in 
response to Endostatin is introduced in the angiogenesis equation [Eq. (1)]
where e0 is the initial EC density. ɛmax is the maximum inhibiting effect of ES on ECs. 
CES50 is the ES concentration that induces 50% of the maximum inhibiting effect. CES is 
the concentration of ES, which satisfies
DES is the diffusion coefficient of ES. RES is the ES elimination rate in the plasma. UI,ex 
is the ES injection rate. Vp is the volume of the plasma. λES is the positive coefficient for 
ES decay of itself.
Simulation setup
The 3D model is defined on a 100 × 100 × 100 grid to cover a 1 mm × 1 mm × 1 mm 
volume, so the grid length corresponds approximately to the size of a tumour cell, i.e. 
10 μm. Two separate lattices are constructed for tumour cells (TCs) and endothelial cells 
(ECs), with the constraint that each grid can contain only one single cell at each time 
point. We assume that there are two main parallel arterioles located at plane y = 100, 
which branch to form capillaries as initial pre-existing vasculature of the model (Fig. 2).
(10)Uv = Q/πR2
(11)Ui = −K∇Pi
(12)∇ · Ui =
LpS
V
(Pv − Pi − σT(πv − πi))
(13)
∂e
∂t
= De∇
2e−∇·
(
φc
1+ σCv
e∇Cv + φhe∇Cf
)
+ ∝r
(
1−
e
e0
)
e
(
1−
ǫmaxCES
CESCES50 + CES
)
(14)
∂CES
∂t
= ∇ · (DES∇CES)+
−RESCES + UI,ex
Vp
− ESCES
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Dirichlet boundary conditions of the chemicals are used in the simulation field. The 
initial condition of ECM density is set to be 1and other chemicals’ concentration (oxy-
gen, VEGF and MDEs) are 0. The chemicals’ concentrations are solved to steady state at 
each time step of the simulation with an inner iteration step of 5 s. The oxygen concen-
tration has been normalized to be 0–1 in the "Results" section.
The total difference of Pv through the two main parallel arterioles from plane x = 100 
to x = 0 is set to be 3.5 mmHg as the driving force of blood in the network (or the bound-
ary condition). The distribution of red blood cells (RBCs) at a microvascular bifurcation 
is calculated based on the blood rheology simulation (see Wu et al. [21]).
Initially, 20 proliferating cells are placed in the central computational area (see the 
tumour morphology in Fig. 2). As the tumour grew with time, the metabolic microen-
vironment such as oxygen, VEGF and other chemicals concentrations are calculated 
accordingly. At the same time, tumour vessels undergo remodelling and collapse in 
response to both chemical environment and haemodynamical environment. As a con-
sequence, the local oxygen supply changes with the updated tumour vasculature, which 
determines the different phenotypes of tumour cells in next time step. The initial con-
centration of anti-angiogenic drug (ES) is e0 = 2.0× 10−9mol L−1, and assumed of hav-
ing an injection dose of ES* =  20 mg kg−1 day−1 after different time point of tumour 
growth (Tinj = 50, Tinj = 100 and Tinj = 150). All simulations were performed on an Intel 
Xeon 3.2 GHz CPU, 24 GB Memory desktop. The parameter values of baseline model 
are listed in Table 2.
Results
Tumour growth and angiogenesis without anti‑angiogenic drug
Figure 3 shows the history of tumour growth and angiogenesis without anti-angiogenic 
drug. Tumour vessels are represented by red tubes. At the early stage, tumour cells 
Fig. 2 The initial pre-existing vasculature and tumour morphology of the model
Page 693 of 700Cai et al. BioMed Eng OnLine 2016, 15(Suppl 2):155
rapidly uptake oxygen diffused from pre-existing vessels, which is known as avascular 
stage of tumour growth (T = 50). The angiogenesis phase is triggered on due to the drop 
of oxygen levels. Well circulated angiogenic vessel networks can be seen at T =  100, 
which suggests that the neo-vasculature generates a new supply of oxygen for further 
tumour growth. In addition, vascularized tumours are more likely to develop dendritic 
structures compared to round tumours in avascular phase. This indicates that tumour 
angiogenesis may reinforce the heterogeneity of tumour microenvironment, favoring a 
more aggressive morphology of solid tumours (T = 200).
The numbers of tumour cells with different phenotypes at different time step are 
presented as curves in Fig. 4. The number of total tumour cells and proliferating cells 
increase continually with time in the simulation. However, the number of quiescent cells 
have a slight reduction in the period of T = 70 to T = 100. At the same time, necrotic 
cells remain linear expansion, due to the inadequate oxygen supply by pre-existing vessel 
network. As a consequence, angiogenesis phase occurs at this time (see Fig. 3). The pro-
liferating cell population shows exponential increase after the emergence of angiogenic 
Table 2 Parameter values used in the simulation
Parameter Value Description Reference
Δl 10 μm Lattice constant
R0 4 μm Origin radius of the capillary
De 10
−9 cm−3 s−1 EC diffusion coefficient [20]
φc 2.6 × 103 cm−3 M−1 s−1 EC chemotaxis coefficient [20]
φh 10
3 cm−3 M−1 s−1 EC haptotaxis coefficient [20]
LTp 2.8 × 10−7 cm (mmHg s)−1 Vessel permeability in tumour tissue [31]
LNp 0.36 × 10−7 cm (mmHg s)−1 Vessel permeability in normal tissue [31]
Pc 3 mmHg Vessel collapse pressure [26]
E 6.5 mmHg Vessel compliance coefficient [26]
b 0.1 Vessel compliance index [26]
Dm 10
−9 cm−3 s−1 MDE diffusion coefficient [24]
δ 1.3 × 102 cm−3 M−1 s−1 ECM degradation coefficient [23]
μT 1.7 × 10−18 Mcells−1 s−1 MDE production by TC [23]
μE 0.3 × 10−18 Mcells−1 s−1 MDE production by EC [23]
λ 1.7 × 10−8 s−1 MDE decay coefficient [24]
Dv 2.9 × 10−7 cm−3 s−1 VEGF diffusion coefficient [20]
χ 10−17 Mcells−1 s−1 VEGF production by TC [32]
ξ 10−3 cm−3 s−1 VEGF production in ECM [23]
ε 10−20 Mcells−1 s−1 VEGF consumption by EC [32]
θ 10−8 s−1 VEGF decay coefficient [32]
e0 2.0 × 10−9 mol L−1 Initial EC density [33]
ɛmax 1 Max inhibiting effect of ES on ECs [33]
CES50 2.288 × 10−8 mol L−1 ES concentration that induces 50% of the maximum 
inhibiting effect
[33]
DES 2.9 × 10−7 cm−3 s−1 Diffusion coefficient of ES [33]
RES 5.54 × 10−5 L s−1 ES elimination rate in the plasma [33]
UI,ex 20 mg (kg × day)−1 ES injection rate [33]
Vp 10
−3 L Volume of the plasma [33]
λES 10
−8/s ES decay coefficient Estimated
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tumour vessels, which demonstrates that the feedback mechanisms of the coupled 
model work well in the simulation.
Tumour growth and angiogenesis with anti‑angiogenic drug
In order to study the influence of anti-angiogenic drug ES on tumour growth and mor-
phology, we tested five drug strategies with different drug concentration and differ-
ent injection time. Compared to base case (Fig.  5a), a low ES concentration is found 
to induce little growth suppression (Fig. 5b), while large doses of ES (ES = 10ES*) can 
produce significant tumour cell apoptosis (Fig. 5c). The effect of different injection time 
of ES on tumour growth is shown in Fig. 5d–f. It is noteworthy that a drastically sup-
pression of tumour size is generated when ES is inserted at simulation time 100, which 
is concomitant with the emergence of angiogenesis phase. As shown by growth history 
curves in Fig. 6, up to 50% of reduction of total tumour cells number can be seen after 
ES treatment on Tinj = 100. However, only 30 and 21% of reduction can achieved respec-
tively if injection time of ES is earlier or later than simulation time 100.
Fig. 3 Time sequence of tumour morphology and angiogenesis during the simulation. Tumour vessels are 
represented by red tubes
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Fig. 4 Growth history of tumour cells with different phenotypes. Blue total tumour cells; red proliferating 
cells; green quiescent cells; black necrotic cells
Fig. 5 Tumour morphology at T = 200 following different anti-angiogenic drug strategies. a Base case 
with no anti-angiogenic drug, as described in “Tumour growth and angiogenesis without anti-angiogenic 
drug” section. b, c The anti-angiogenic drug ES is inserted at Tinj = 100, with different drug concentrations 
(ES = 0.1ES*, ES = 10ES*). d, e, f The effect of ES on tumour growth with same dose but different injection 
time, Tinj = 50, 100, 150 respectively
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Metabolical and haemodynamical microenvironment
The model predicts the chemical and haemodynamical substances distribution includ-
ing oxygen, VEGF, interstitial pressure and vessel radius, as shown in Fig. 7. The tumour 
centre is always in a hypoxic state, while high concentration of oxygen occurred near 
Fig. 6 Growth history curves of total tumour cells following different anti-angiogenic drug strategies
Fig. 7 Chemical and haemodynamical microenvironment on T = 200, at plane z = 20. a Oxygen distribu-
tion. b VEGF distribution. c Interstitial pressure. d Vessel radius distribution. Arrow indicates the vessel dilation. 
Intensity: red (high), blue (low)
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the tumour edge due to the localized angiogenic vasculature at the tumour periphery 
(Fig. 7a). VEGF has a high density inside the tumour associated with hypoxic tumour 
cells, attracting neo-vessels growth towards the tumour (Fig.  7b). Interstitial pressure 
Pi is significantly higher than that of surrounding tissue and drops dramatically in the 
tumour margin (Fig.  7c), which compromises the delivery of therapeutic agents both 
across the blood vessel wall and interstitium in tumours. Vessel radius shows unevenly 
distributed, with few dilated functional vessels left in the tumour centre (Fig. 7d, arrow). 
The large variation in vessel diameters will increase the flow resistance in tumours 
microvasculature, which has been observed in published experiments [5].
Parameter sensitivity
In the current model, the main factors that directly influence ECs distribution are the 
chemotaxis of VEGF, the haptotaxis of ECM, the vessel remodelling in response to local 
haemodynamical microenvironment and the inhibition effect due to ES treatment. The 
sensitivity of tumour growth to the important parameters are analyzed, including chem-
otaxis coefficient φc, haptotaxis coefficient φh, wall permeability of tumour capillaries Lp 
and maximum inhibiting effect of ES ɛmax. The variation ranges of tested parameters are 
±1 and ±10% from their default values listed in Table 2. As shown in Fig. 8, the number 
of total tumour cells is quite robust with respect to varied parameters (less than 15% 
changes). The most sensitive parameter to this model is the maximum inhibiting effect 
of ES ɛmax.
Discussion
In this paper, we proposed a multi-scale coupled modelling system to investigate the 
dynamic process of tumour growth and angiogenesis in response to the changes in 
chemical and haemodynamical microenvironment caused by anti-angiogenic therapy. At 
tissue level, we considered tumour growth, tumour angiogenesis and vessel remodelling. 
Fig. 8 Percentage changes of number of total tumour cells with respect to varied parameters
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Tumour growth and neo-vessel growth are coupled by the chemical microenvironment 
including oxygen, VEGF, ECM and MDE, which are described by continuous partial 
differential equations. At the same time, haemodynamic calculation is carried out by 
coupling intravascular blood flow and interstitial fluid flow. According to the microen-
vironmental information, detailed and comprehensive mechanisms of tumour cell phe-
notype and endothelial cell proliferation and migration are generated at cellular level, 
which in turn influence the modelling at intratumoral and tissue levels. In addition, we 
extended the model to study the dynamic changes of tumour growth in response to anti-
angiogenic therapy. Anti-angiogenic drug ES is assumed to target immature vessels and 
may cause endothelial cell apoptosis.
Simulation results revealed multiple characteristics of tumour progression, includ-
ing tumour expansion, morphology changes and angiogenesis. The growth curves of 
cell population with different cell phenotypes are consistent with the pathophysiological 
knowledge. Furthermore, different anti-angiogenic drug strategies are designed to test the 
influence of ES on tumour growth and morphology. The largest reduction of tumour size 
is found when ES is injected at simulation time 100, which is concomitant with the emer-
gence of angiogenesis phase. With pharmacokinetics information of specific anti-angio-
genic drugs, the proposed model can be adopted for cancer drug discovery and testing.
There are a few major limitations of the present work. On calculating the tumour 
mechanical environment, only interstitial fluid static pressure was included. Mechanical 
stress caused by the rapid proliferation of tumour cells was not simulated in the model. 
This solid mechanical stress may influence tumour cell behaviour. In addition, although 
most of the simulation parameters were set based on published experimental data, some 
of them cannot be found, such as tumour migration speed.
Conclusions
A multi-scale coupled modelling system to investigate the dynamic process of tumour 
growth and angiogenesis in response to the changes in chemical and haemodynamical 
microenvironment during the anti-angiogenic therapy, is established. The simulation 
results demonstrate the inhibition of tumour growth and progression due to the reduc-
tion of neo-vasculature in response to anti-angiogenic therapy. Different anti-angiogenic 
drug strategies can be designed based on the proposed mathematical model, to test the 
influence of anti-angiogenic drug on tumour growth and morphology, with pharmacoki-
netics information of specific drugs
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